StreetInsider.com News Articles

Form 8-K Valion Bio, Inc. For: Oct 26

Tue, 27 Oct 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20261027/27236130.html

Valion Bio weighs sale of CDMO unit after unsolicited interest

Mon, 26 Oct 2026 08:03:01 -0400

Valion Bio, Inc. (NASDAQ: VBIO) announced it has received unsolicited acquisition inquiries from third parties regarding its wholly owned contract development and manufacturing organization (CDMO), Velocity Bioworks, and has entered into preliminary discussions while evaluating strategic options for the subsidiary.

The company has retained a nationally recognized investment banking firm to advise its board on a potential transaction. Key considerations include proposed valuation and terms, execution certainty, and potential net proceeds. Valion stated that retaining production rights and securing continued manufacturing for its lead drug candidate, Entolimod, would be a priority in any transaction.

"Our strategic review is focused on determining how

Valion Bio weighs sale of CDMO unit after unsolicited interest

Mon, 26 Oct 2026 08:03:01 -0400

"Our strategic review is focused on determining how

Valion Bio weighs sale of CDMO unit after unsolicited interest

Mon, 26 Oct 2026 08:03:01 -0400

"Our strategic review is focused on determining how

Form 8-K Valion Bio, Inc. For: Oct 26

Mon, 26 Oct 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20261026/27230922.html

Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options

Mon, 26 Oct 2026 08:00:00 -0400

SAN ANTONIO, TX / ACCESS Newswire / October 26, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today announced that it has received unsolicited acquisition inquiries from independent third parties concerning its wholly owned contract development and manufacturing organization ("CDMO"), Velocity Bioworks ("Velocity"). The Company has entered into preliminary discussions with these interested parties while continuing to evaluate a range of strategic options for Velocity.

These discussions are consistent with the strategic priorities outlined in

Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options

Mon, 26 Oct 2026 08:00:00 -0400

These discussions are consistent with the strategic priorities outlined in

Form 8-K Valion Bio, Inc. For: Oct 21

Thu, 22 Oct 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20261022/27219330.html

Valion Bio outlines three-part strategy under new interim CEO

Wed, 21 Oct 2026 08:02:22 -0400

Valion Bio, Inc. (NASDAQ: VBIO), a clinical-stage biopharmaceutical company, has outlined a three-part strategic agenda following the first 30 days of Dean Zikria's tenure as Interim Chief Executive Officer, according to a company statement.

The agenda centers on advancing the company's clinical pipeline, building commercial activity at its contract development and manufacturing subsidiary Velocity Bioworks, and evaluating strategic options for that subsidiary, which may include partnerships, licensing deals, joint ventures, or a sale.

Valion's lead drug candidate, Entolimod, is being developed as a potential medical countermeasure for Acute Radiation Syndrome. The program has received approximately $35.6 million in non-dilutive U.S. government funding

Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value

Wed, 21 Oct 2026 08:00:00 -0400

SAN ANTONIO, TX / ACCESS Newswire / October 21, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today shared the initial findings and priorities from Dean Zikria's first 30 days as Interim Chief Executive Officer. Mr. Zikria's strategic review has set a focused agenda built on three priorities:

Advancing the development of Entolimod and other pipeline assets;
Pursuing customer and revenue capabilities for Velocity Bioworks ("Velocity"), the Company's wholly owned contract development and manufacturing organization

Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value

Wed, 21 Oct 2026 08:00:00 -0400

Advancing the development of Entolimod and other pipeline assets;
Pursuing customer and revenue capabilities for Velocity Bioworks ("Velocity"), the Company's wholly owned contract development and manufacturing organization

Form EFFECT Valion Bio, Inc.

Wed, 21 Oct 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20261021/27212470.html

Form EFFECT Valion Bio, Inc.

Wed, 21 Oct 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20261021/27212484.html

Form 424B3 Valion Bio, Inc.

Wed, 21 Oct 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20261021/27212336.html

Form S-3 Valion Bio, Inc.

Fri, 16 Oct 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20261016/27198770.html

Form DEF 14A Valion Bio, Inc. For: Nov 12

Fri, 16 Oct 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20261016/27198446.html

Valion Bio unit completes early NMR feasibility test with LarmorBio

Thu, 15 Oct 2026 08:06:26 -0400

Valion Bio, Inc. (NASDAQ: VBIO) announced that Velocity Bioworks, its wholly owned biologics contract development and manufacturing organization, has completed an initial feasibility evaluation of LarmorBio's BioScan-NMR™ platform, according to a press release dated October 15, 2026.

The evaluation found a correlation between signals measured by the BioScan-NMR™ platform and optical density at 600 nm, a standard measurement used to estimate cell density in liquid cultures. The result suggests the platform has the potential to track microbial growth during fermentation processes.

BioScan-NMR™ is being developed as a process analytical technology for biologics manufacturing. LarmorBio is designing the platform to provide real-time, continuous

Form 8-K Valion Bio, Inc. For: Oct 15

Thu, 15 Oct 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20261015/27189913.html

Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone

Thu, 15 Oct 2026 08:00:00 -0400

SAN ANTONIO, TX AND WALTHAM, MA / ACCESS Newswire / October 15, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company") and LarmorBio, Inc. ("LarmorBio") today announced that Velocity Bioworks, Valion's wholly owned biologics contract development and manufacturing organization ("CDMO") subsidiary, has successfully completed an initial feasibility evaluation of LarmorBio's BioScan-NMR^™ platform.

BioScan-NMR™ is being developed to create a new class of process analytical technology ("PAT") for biologics manufacturing.
The initial feasibility evaluation demonstrated that nuclear magnetic resonance ("NMR") measurements have the potential to track microbial growth during a fermentation process.
Building on

Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone

Thu, 15 Oct 2026 08:00:00 -0400

BioScan-NMR™ is being developed to create a new class of process analytical technology ("PAT") for biologics manufacturing.
The initial feasibility evaluation demonstrated that nuclear magnetic resonance ("NMR") measurements have the potential to track microbial growth during a fermentation process.
Building on

Form 8-K Valion Bio, Inc. For: Oct 14

Wed, 14 Oct 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20261014/27184183.html

With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge

Wed, 14 Oct 2026 08:15:00 -0400

SAN ANTONIO, TX / ACCESS Newswire / October 14, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today highlighted the capabilities of its wholly owned contract development and manufacturing organization ("CDMO"), Velocity Bioworks. Velocity Bioworks ("Velocity") is part of Valion's own domestic biologics supply chain, supporting the Company's development strategy for its lead candidate, Entolimod, which is being developed as a potential medical countermeasure for Acute Radiation Syndrome.

Velocity Bioworks can support biotechnology companies evaluating

With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge

Wed, 14 Oct 2026 08:15:00 -0400

Velocity Bioworks can support biotechnology companies evaluating

Valion Bio develops oral form of radiation countermeasure Entolimod

Fri, 09 Oct 2026 07:51:37 -0400

Valion Bio, Inc. (Nasdaq: VBIO), a clinical-stage biopharmaceutical company, has completed formulation work on an oral mucosal version of its investigational drug Entolimod, developed for acute radiation syndrome (ARS), according to a company statement.

Entolimod has historically been administered by intramuscular injection. The new formulation was developed in collaboration with Shear Kershman Laboratories using its proprietary BioViscid™ drug-delivery platform and is designed to enable absorption through the oral mucosa as a needle-free alternative.

The drug candidate is being developed under the U.S. Food and Drug Administration's Animal Rule, which permits drug approvals based on animal efficacy studies when human trials are not

Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand

Fri, 09 Oct 2026 07:45:00 -0400

SAN ANTONIO, TX / ACCESS Newswire / October 9, 2026 / As nuclear power assumes an increasingly important role in meeting the growing electricity requirements of artificial intelligence, data centers and other digital infrastructure, the expansion of the U.S. nuclear-energy landscape that has been increasingly making headlines across the country is also highlighting the importance of resilient emergency preparedness and medical countermeasures for potential radiological and nuclear events.

Against this backdrop, Valion Bio, Inc. (Nasdaq:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for